These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26571838)

  • 1. [Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].
    Bespalov VG; Kireeva GS; Belyaeva OA; Senchik KY; Stukov AN; Gafton GI; Soloviev LA; Vasilchenko MV; Guseinov KD; Alexeev VV; Belyaev AM
    Vopr Onkol; 2015; 61(4):647-52. PubMed ID: 26571838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumor effect of dioxadet in intraperitoneal chemoperfusion treatment for advanced ovarian cancer in experimental setting].
    Bespalov VG; Beliaeva OA; Kireeva GS; Senchik KIu; Stukov AN; Aristova VA; Vyshinskaia EA; Kon'kov SA; Krylova IA; Semënov AL; Maĭdin MA; Aleksandrov VA; Beliaev AM
    Vopr Onkol; 2014; 60(2):72-9. PubMed ID: 24919266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model.
    Bespalov VG; Kireeva GS; Belyaeva OA; Kalinin OE; Senchik KY; Stukov AN; Gafton GI; Guseynov KD; Belyaev AM
    J Surg Oncol; 2016 Mar; 113(4):438-42. PubMed ID: 26710749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental technology of chemoperfusion treatment for abdominal carcinomatosis in ovarian cancer].
    Beliaeva OA; Bespalov VG; Senchik KIu; Kireeva GS; Stukov AN; Aristova VA; Ivantsov AO; Vyshinskaia EA; Maĭdin MA; Semënov AL; Aleksandrov VA; Beliaev AM
    Vopr Onkol; 2014; 60(1):71-9. PubMed ID: 24772620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer.
    Bespalov VG; Alvovsky IK; Tochilnikov GV; Stukov AN; Vyshinskaya EA; Semenov AL; Vasilyeva IN; Belyaeva OA; Kireeva GS; Senchik KY; Zhilinskaya NT; Von JD; Krasilnikova LA; Alexandrov VA; Khromov-Borisov NN; Baranenko DA; Belyaev AM
    Int J Hyperthermia; 2018 Aug; 34(5):545-550. PubMed ID: 28893108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer.
    Bespalov VG; Kireeva GS; Belyaeva OA; Senchik KY; Stukov AN; Maydin MA; Semenov AL; Gafton GI; Guseynov KD; Belyaev AM
    J Chemother; 2016 Jun; 28(3):203-9. PubMed ID: 26027427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
    Bespalov VG; Vyshinskaya EA; Vasilieva IN; Maidin MA; Semenov AL; Stukov AN; Kireeva GS; Belyaeva OA; Kopteva OS; Krasilnikova LA; Alexandrov VA; Belyaev AM
    Vopr Onkol; 2015; 61(4):634-41. PubMed ID: 26571836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.
    Cascales Campos PA; Gil Martínez J; Galindo Fernández PJ; Gil Gómez E; Martínez Frutos IM; Parrilla Paricio P
    Eur J Surg Oncol; 2011 Jun; 37(6):543-8. PubMed ID: 21489742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
    Zeamari S; Floot B; van der Vange N; Stewart FA
    Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
    Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
    J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
    Cascales Campos P; Gil J; Parrilla P
    Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
    Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
    BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
    Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
    Salvatorelli E; De Tursi M; Menna P; Carella C; Massari R; Colasante A; Iacobelli S; Minotti G
    Drug Metab Dispos; 2012 Dec; 40(12):2365-73. PubMed ID: 22972909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
    Ansaloni L; Coccolini F; Morosi L; Ballerini A; Ceresoli M; Grosso G; Bertoli P; Busci LM; Lotti M; Cambria F; Pisano M; Rossetti D; Frigerio L; D'Incalci M; Zucchetti M
    Br J Cancer; 2015 Jan; 112(2):306-12. PubMed ID: 25461804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
    Ceelen WP; Van Nieuwenhove Y; Van Belle S; Denys H; Pattyn P
    Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulation of Chemoperfusion Treatment for Abdominal Carcinomatosis.
    Bespalov VG; Belyaeva OA; Kireeva GS; Senchik KY; Stukov AN; Belyaev AM
    Bull Exp Biol Med; 2015 May; 159(1):81-4. PubMed ID: 26033596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined cytoreductive surgery and intraoperative hyperthermic chemo-perfusion for peritoneal carcinomatosis: methods, postoperative features and end results].
    Tarasov VA; Vinogradova MV; Norbaev ShE; Sharov IuK; Stavrovietskiĭ VV; Adueva SA; Blium MB
    Vopr Onkol; 2006; 52(6):638-42. PubMed ID: 17338240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.